Impact of kidney function on the safety and efficacy of insulin degludec versus insulin glargine U300 in people with type 2 diabetes: A post hoc analysis of the CONCLUDE trial

被引：5
|
作者：
Pieber, Thomas R. [1 ]
Bajaj, Harpreet S. [2 ]
Heller, Simon R. [3 ]
Jia, Ting [4 ]
Khunti, Kamlesh [5 ]
Klonoff, David C. [6 ]
Ladelund, Steen [4 ]
Leiter, Lawrence A. [7 ]
Wagner, Lily [4 ]
Philis-Tsimikas, Athena [8 ]
机构：
[1] Med Univ Graz, Dept Internal Med, Div Endocrinol & Diabetol, Auenbruggerpl 2, A-8036 Graz, Austria
[2] LMC Diabet & Endocrinol, Brampton, ON, Canada
[3] Univ Sheffield, Acad Unit Diabet Endocrinol & Metab, Sheffield, S Yorkshire, England
[4] Novo Nordisk AS, Soborg, Denmark
[5] Univ Leicester, Diabet Res Ctr, Leicester, Leics, England
[6] Mills Peninsula Med Ctr, Diabet Res Inst, San Mateo, CA USA
[7] Univ Toronto, St Michaels Hosp, Div Endocrinol & Metab, Li Ka Shing Knowledge Inst, Toronto, ON, Canada
[8] Scripps Whittier Diabet Inst, La Jolla, CA USA
来源：
DIABETES OBESITY & METABOLISM | 2022年 / 24卷 / 02期
关键词：
insulin analogues; insulin therapy; type; 2; diabetes; 300; U/ML; HYPOGLYCEMIA; VARIABILITY; THERAPY; DISEASE;
D O I：
10.1111/dom.14564
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：332 / 336
页数：5
相关论文
共 50 条
  • [21] Insulin doses requirements in patients with type 1 diabetes using glargine U300 or degludec in routine clinical practice
    Carral San Laureano, Florentino
    Tome Fernandez-Ladreda, Mariana
    Jimenez Millan, Ana Isabel
    Garcia Calzado, Concepcion
    Ayala Ortega, Maria del Carmen
    JOURNAL OF INVESTIGATIVE MEDICINE, 2021, 69 (05) : 983 - 988
  • [22] A Review of the Clinical Efficacy and Safety of Insulin Degludec and Glargine 300 U/mL in the Treatment of Diabetes Mellitus
    Woo, Vincent C.
    CLINICAL THERAPEUTICS, 2017, 39 (08) : S12 - S33
  • [23] Effectiveness and Safety of the Insulin Degludec U100 vs. Glargine U300 in People with Type 1 diabetes-The IneoxPlus Real-World Study
    De Adana, Maria S. Ruiz, Sr.
    Dominguez-Lopez, Marta E.
    Mora, Maria Del Rosario Vallejo
    Colomo, Natalia
    Linares, Francisca
    Morillas, Virginia
    Herrera, Maria Jose Vallejo
    Gallardo, Silvia Patricia Alonso
    Fuentes, Maria Teresa Padilla
    Vela, Luis I. Navas
    Maldonado-Araque, Cristina
    Olveira, Gabriel
    Martinez, Gemma Rojo
    DIABETES, 2023, 72
  • [24] Effects of Insulin Degludec and Insulin Glargine U300 on Interday Glycemic Variability in Individuals with Type 1 Diabetes: A Multicenter, Randomized, Crossover Study
    Miura, Hiroshi
    Sakaguchi, Kazuhiko
    Kaneko, Akihiro
    Ito, Jun
    Morita, Yasuko
    Yamada, Tomoko
    Otowa-Suematsu, Natsu
    So, Anna
    Nakamura, Tomoaki
    Komada, Hisako
    Okada, Yuko
    Hirota, Yushi
    Tamori, Yoshikazu
    Ogawa, Wataru
    DIABETES, 2020, 69
  • [25] COST-UTILITY ANALYSIS OF INSULIN GLARGINE 300 U/ML VERSUS INSULIN GLARGINE 100 U/ML AND INSULIN DEGLUDEC 100 U/ML IN PATIENTS WITH TYPE 2 DIABETES MELLITUS IN CROATIA
    Bogdanovic, M.
    Fournier, M.
    Vitezic, D.
    VALUE IN HEALTH, 2018, 21 : S131 - S132
  • [26] COST-UTILITY ANALYSIS OF INSULIN GLARGINE 300 U/ML VERSUS INSULIN GLARGINE 100 U/ML AND INSULIN DEGLUDEC 100 U/ML IN PATIENTS WITH TYPE 2 DIABETES MELLITUS IN BULGARIA
    Bogdanovic, M.
    Mihajlovic, J.
    Fournier, M.
    VALUE IN HEALTH, 2018, 21 : S133 - S133
  • [27] Differential glycaemic control with basal insulin glargine 300 U/mL versus degludec 100 U/mL according to kidney function in type 2 diabetes: A subanalysis from the BRIGHT trial
    Haluzik, Martin
    Cheng, Alice
    Mueller-Wieland, Dirk
    Westerbacka, Jukka
    Bosnyak, Zsolt
    Lauand, Felipe
    Melas-Melt, Lydie
    Karalliedde, Janaka
    Rosenstock, Julio
    Bolli, Geremia B.
    DIABETES OBESITY & METABOLISM, 2020, 22 (08): : 1369 - 1377
  • [28] Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes
    Marso, Steven P.
    McGuire, Darren K.
    Zinman, Bernard
    Poulter, Neil R.
    Emerson, Scott S.
    Pieber, Thomas R.
    Pratley, Richard E.
    Haahr, Poul-Martin
    Lange, Martin
    Brown-Frandsen, Kirstine
    Moses, Alan
    Skibsted, Simon
    Kvist, Kajsa
    Buse, John B.
    Buse, John B.
    Hansen, Liliana
    Marso, Steven P.
    Rabol, Rasmus
    Zinman, Bernard
    Bethel, Angelyn
    de Lemos, James A.
    Senn, Stephen
    Schwamm, Lee
    Timmis, Adam
    Alshekhlee, Amer
    Bach, Richard G.
    Bertram, Therese M.
    Chaitman, Bernard R.
    Cruz-Flores, Salvador
    Eckstein, Jane F.
    Feen, Eliahu S.
    Fisher, Simon J.
    Gosselin, Gilbert
    Lim, Michael J.
    Rosenzweig, James L.
    Sherwin, Robert S.
    Tobin, Garry S.
    Vetrovec, George
    Ziemer, David C.
    Daugaard, Gedske
    Ozlem, Er
    Pollak, Michael
    Sengelov, Lisa
    Ahn, Yu-Bae
    Amod, Aslam
    Benroubi, Mariana
    Boonyavarakul, Apussanee
    Canecki-Varzic, Silvija
    Consoli, Agostino
    Eliaschewitz, Freddy G.
    NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (08): : 723 - 732
  • [29] Clinical Outcome Assessment of the Effectiveness of Insulin Degludec (Degludec) in Real-life Medical Practice (CONFIRM)-A Comparative Effectiveness Study of Degludec and Insulin Glargine 300U/mL (Glargine U300) in Insulin-Naive Patients with Type 2 Diabetes (T2D)
    Tibaldi, Joseph
    Haldrup, Steffen
    Sandberg, Viktor
    Wolden, Michael L.
    Rodbard, Helena W.
    DIABETES, 2018, 67
  • [30] Glycaemic variability and risk for hypoglycaemia on insulin glargine 300 U/ml versus insulin glargine 100 U/ml in people with type 2 diabetes
    Kovatchev, B.
    Meng, Z.
    Breton, M.
    Leroy, B.
    Cali, A.
    Perfetti, R.
    DIABETOLOGIA, 2017, 60 : S36 - S37
12345